WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the UBS Targeted Protein Degradation (TPD) Day taking place virtually on July 15, 2024.
Fireside Chat Details:
Event: UBS TPD Day
Date/Time: Monday, July 15, 2024 from 12:00 pm ET – 12:30 pm ET
A live webcast will be available on the Investors section of the company’s website at www.c4therapeutics.com. An archived replay of the webcast will be available for approximately 30 days following the live event.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
Contacts:
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
SHANGHAI, June 30, 2025 /PRNewswire/ -- In an era where real-time treatment agility defines competitive…
NEW YORK, June 30, 2025 /PRNewswire/ -- For individuals managing respiratory conditions, every breath matters—and…
CAMBRIDGE, Mass., June 29, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in…
Market Growth Driven by Outsourcing Preferences, Advanced Manufacturing Technologies, Regulatory Compliance Expertise, and Industry 4.0…
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select…
The 2025 update to the Atom One and Atom 2 models introduces enhanced wireless charging,…